New ambition, new image!

Ophiomics was founded in 2015 as clinical testing laboratory. In 2020, with the support of the EIC Accelerator grant and from the EIC Fund, we pivoted our business model to develop a new IVD product that, assisted by an algorithm we developed, could stratify liver cancer patients for curative intent surgical approaches: HepatoPredict was launched in late 2022, already CE IVD marked! In December 2022 we concluded an investment round with BlueCrow Capital, in terms that allowed us to think bigger, and implement our vision of becoming an “innovation engine” that develops new AI/Machine Learning assisted In Vitro diagnostic Solutions to support clinical decisions in oncology. We believed it was time to refresh our image, and also have a website that reflects we we are today. So… welcome to our new (web) home!